Individuals utilizing Wegovy report decreased appetite sounds and enhanced psychological health
In a significant development, Novo Nordisk has announced the results from the INFORM survey, which investigates the impact of semaglutide (Wegovy) on weight management. The findings, presented at the European Association for the Study of Diabetes (EASD) 2025 in Vienna, Austria, add to the growing body of evidence supporting the broad health benefits of semaglutide in individuals with obesity.
The survey found that substantial majorities of respondents reported developing a healthier lifestyle (76%) and healthier habits (80%). Moreover, around 8 in 10 (83%) of individuals in the study were satisfied with their Wegovy treatment.
One of the intriguing aspects of the survey is the improvement in mental health. Around two-thirds (64%) of respondents reported that their mental health improved since starting Wegovy treatment. Furthermore, the decline in the number of people experiencing constant thoughts about food throughout the day was 46%, dropping from 62% before starting Wegovy to 16% on Wegovy.
Food noise, or unwanted and intrusive thoughts about food, can significantly affect mental well-being, quality of life, and weight loss efforts. It's encouraging to note that individuals taking Wegovy experienced a substantial drop in food noise. In fact, the proportion of participants who reported that food noise had a negative effect on their lives decreased from 60% before starting treatment to 20% for respondents on Wegovy treatment.
Wegovy may help quiet disruptive thoughts about food, support improved mental wellbeing, and help enable people to live healthier lives. Filip Knop, senior vice president and head of Medical & Translational Science at Novo Nordisk, commented on these new data, stating, "It is encouraging to see these new data from people using Wegovy."
Novo Nordisk continues to investigate how obesity impacts individuals' day-to-day lives. An upcoming presentation at EASD will highlight eating behavior and control of eating with semaglutide from the STEP UP clinical trial findings. The leader of the clinical study, investigating how semaglutide affects eating behavior and control in people with overweight, is not explicitly mentioned in the provided search results.
In conclusion, the INFORM survey results provide compelling evidence that Wegovy treatment is associated with notable improvements in mental well-being and lifestyle for people with obesity. These findings could pave the way for a more comprehensive understanding of the role of semaglutide in managing obesity and its associated comorbidities.
Read also:
- Rise in Flu Cases: Timing and Reasons Explored by Medical Experts for Flu Vaccination
- Nursing Infants: Advantages, Factors to Ponder, Guidelines, Essential Gear
- Anticipated Increase in Uninsured Residents to Pose Challenge for Local Healthcare Infrastructure
- Accusations of poor care and supposedly poor hygienic standards at LaSalle Hospital
